Cargando…

Roflumilast in COPD: a Brazilian perspective

Detalles Bibliográficos
Autores principales:	Stirbulov, Roberto, Jardim, José R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571931/ https://www.ncbi.nlm.nih.gov/pubmed/26388690 http://dx.doi.org/10.2147/COPD.S64455

Ejemplares similares

Does roflumilast induce phagocytic activity in COPD patients?
por: Ghosh, Baishakhi, et al.
Publicado: (2015)

Vulnerable COPD patients with comorbidities: the role of roflumilast
por: Lipari, Melissa, et al.
Publicado: (2014)

Efficacy and Safety of Roflumilast in Korean Patients with COPD
por: Lee, Jae Seung, et al.
Publicado: (2016)

Roflumilast: a review of its use in the treatment of COPD
por: Wedzicha, Jadwiga A, et al.
Publicado: (2016)

New therapeutic options in the management of COPD – focus on roflumilast
por: Antoniu, Sabina Antonela
Publicado: (2011)

Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap
por: Zhang, Xiaoli, et al.
Publicado: (2018)

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010)

Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD
por: Park, Tai Sun, et al.
Publicado: (2019)

A Way to Increase the Bioaccesibility and Photostability of Roflumilast, a COPD Treatment, by Cyclodextrin Monomers
por: Matencio, Adrián, et al.
Publicado: (2019)

PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast
por: Boswell-Smith, Victoria, et al.
Publicado: (2007)

Glucocorticoid Receptor α Mediates Roflumilast’s Ability to Restore Dexamethasone Sensitivity in COPD
por: Reddy, Aravind T, et al.
Publicado: (2020)

Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations
por: Field, Stephen K.
Publicado: (2011)

Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
por: Porpodis, Konstantinos, et al.
Publicado: (2015)

Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis
por: Yuan, Lianfang, et al.
Publicado: (2016)

Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD
por: Watz, Henrik, et al.
Publicado: (2018)

The Role of the Pharmacist in Optimizing Outcomes With Roflumilast, a PDE4 Inhibitor for the Treatment of COPD
por: Williams, Dennis
Publicado: (2020)

Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD
por: Puhan, Milo A., et al.
Publicado: (2015)

Erratum for “Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations”
Publicado: (2012)

Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
por: Rennard, Stephen I, et al.
Publicado: (2011)

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland
por: Samyshkin, Yevgeniy, et al.
Publicado: (2013)

Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist
por: Milara, Javier, et al.
Publicado: (2015)

Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population
por: Moll, Keran, et al.
Publicado: (2015)

Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol
por: Calverley, Peter MA, et al.
Publicado: (2012)

Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA
por: Kardos, Peter, et al.
Publicado: (2018)

Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom
por: Samyshkin, Yevgeniy, et al.
Publicado: (2013)

Implementing lessons learned from previous bronchial biopsy trials in a new randomized controlled COPD biopsy trial with roflumilast
por: Barnes, Neil C, et al.
Publicado: (2014)

Roflumilast partially reverses smoke-induced mucociliary dysfunction
por: Schmid, Andreas, et al.
Publicado: (2015)

Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy
por: Ring, Hans Christian, et al.
Publicado: (2022)

Periostin as an important biomarker of inflammatory phenotype T2 in Brazilian asthma patients
por: Baldo, Danielle Cristiane, et al.
Publicado: (2023)

The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials
por: Jafari Andarian, Saeideh, et al.
Publicado: (2016)

Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects
por: Gauvreau, Gail M, et al.
Publicado: (2011)

Roflumilast Suppresses Adipogenic Differentiation via AMPK Mediated Pathway
por: Xu, Wan, et al.
Publicado: (2021)

Updated Perspectives on the Role of Biomechanics in COPD: Considerations for the Clinician [Letter]
por: Bordoni, Bruno
Publicado: (2022)

Characterization of Resveratrol, Oxyresveratrol, Piceatannol and Roflumilast as Modulators of Phosphodiesterase Activity. Study of Yeast Lifespan
por: Matencio, Adrián, et al.
Publicado: (2020)

Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice
por: Martorana, Piero A, et al.
Publicado: (2008)

Rapid Liquid Chromatographic Method for the Determination of Roflumilast in the Presence of Degradation Products
por: Barhate, V D, et al.
Publicado: (2010)

Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease
por: Kim, Kyung Hoon, et al.
Publicado: (2017)

Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients
por: Liu, Dong-yang, et al.
Publicado: (2018)

Can roflumilast become steroid-sparing alternative in the treatment of COVID-19?
por: Shah, Chirag A.
Publicado: (2020)

Rectal roflumilast improves trinitrobenzenesulfonic acid-induced chronic colitis in rats
por: Shaikh-Omar, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ohh9akqmab6ck18938420sv55u